The European Medicines Agency (EMA) stressed on Tuesday (16 March) that the benefits of AstraZeneca's Covid-19 vaccine continue to outweigh the risks - after a dozen member states suspended its use in national inoculation programmes over blood-clot concerns.
"A situation like this is not unexpected when you vaccinate millions of people. Our role is to evaluate these so we can figure out is this a real side effect or is it a coincidence," EMA executive director Emer Cooke told a news con...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? LoginElena is EUobserver's editor-in-chief. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.
Elena is EUobserver's editor-in-chief. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.